Senseonics Holdings, Inc.SENSEarnings & Financial Report
Senseonics Holdings, Inc. is a medical technology company focused on developing and commercializing long-term implantable continuous glucose monitoring (CGM) systems for people living with diabetes. Its flagship Eversense product line offers extended wear duration, serving markets across North America, Europe and other global regions in the diabetes care segment.
Revenue
$6.6M
Gross Profit
$3.1M
Operating Profit
$-14.3M
Net Profit
$-14.5M
Gross Margin
46.9%
Operating Margin
-215.4%
Net Margin
-218.1%
YoY Growth
36.7%
EPS
$-0.02
Senseonics Holdings, Inc. Q2 FY2025 Financial Summary
Senseonics Holdings, Inc. reported revenue of $6.6M (up 36.7% YoY) for Q2 FY2025, with a net profit of $-14.5M (up 28.5% YoY) (-218.1% margin). Cost of goods sold was $3.5M, operating expenses totaled $17.4M.
Key Financial Metrics
| Total Revenue | $6.6M |
|---|---|
| Net Profit | $-14.5M |
| Gross Margin | 46.9% |
| Operating Margin | -215.4% |
| Report Period | Q2 FY2025 |
Senseonics Holdings, Inc. Annual Revenue by Year
Senseonics Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $35.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $35.3M |
| 2024 | $22.5M |
| 2023 | $22.4M |
| 2022 | $16.4M |
Senseonics Holdings, Inc. Quarterly Revenue & Net Profit History
Senseonics Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $14.3M | +71.8% | $-20.8M | -146.1% |
| Q3 FY2025 | $8.1M | +89.9% | $-19.5M | -241.3% |
| Q2 FY2025 | $6.6M | +36.7% | $-14.5M | -218.1% |
| Q1 FY2025 | $6.3M | +24.0% | $-14.3M | -227.9% |
| Q4 FY2024 | $8.3M | +3.3% | $-15.5M | -186.5% |
| Q3 FY2024 | $4.3M | -30.1% | $-24.0M | -562.4% |
| Q2 FY2024 | $4.9M | +17.9% | $-20.3M | -417.0% |
| Q1 FY2024 | $5.0M | +22.0% | $-18.9M | -374.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M | $4.9M | $4.3M | $8.3M | $6.3M | $6.6M | $8.1M | $14.3M |
| YoY Growth | 22.0% | 17.9% | -30.1% | 3.3% | 24.0% | 36.7% | 89.9% | 71.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $126.5M | $111.6M | $96.3M | $100.4M | $87.2M | $150.3M | $139.9M | $126.3M |
| Liabilities | $69.9M | $73.3M | $75.9M | $79.3M | $52.0M | $55.6M | $61.8M | $65.2M |
| Equity | $19.0M | $578000 | $-17.2M | $-16.6M | $35.2M | $94.7M | $78.2M | $61.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.3M | $-11.1M | $-14.8M | $-14.2M | $-16.1M | $-9.3M | $-15.8M | $-18.0M |